EDIT - Editas strengthens Q1 liquidity despite rising net loss; names new chief scientific officer

Announcing its Q1 2021 results, Editas Medicine (EDIT) said that the cash and equivalents as of March 31 have improved to $6.5M indicating ~41.3% growth from the 2020-year end, and along with interest, the liquidity could fund its operations and capex until at least 2023.However, the company’s net loss has expanded by ~50.4% YoY to $56.7M after R&D and SG & A expenses climbed to ~$41.9M and $21.4M implying ~21.2% and 20.2% YoY growth, respectively.The collaboration and other research and development revenues have reached $6.5M with ~14.0% YoY growth.On the clinical front, Editas announced that its BRILLIANCE trial of EDIT-101 for Leber Congenital Amaurosis 10 (LCA10) is in progress with clinical data from the first two cohorts expected by the end of 2021.The company is recruiting participants for the RUBY trial of EDIT-301 for sickle cell disease. And the dosing is expected to begin by the end of 2021.Editas also announced the appointment

For further details see:

Editas strengthens Q1 liquidity despite rising net loss; names new chief scientific officer